Pacific Biosciences of California

$1.20
(as of May 8, 3:57 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Pacific Biosciences of California

Stock Price
$1.20
Ticker Symbol
PACB
Exchange
NASDAQ

Industry Information for Pacific Biosciences of California

Sector
Healthcare
Industry
Medical Devices

Company Description for Pacific Biosciences of California

Country
USA
Full Time Employees
575

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Fundamentals for Pacific Biosciences of California

Market Capitalization
$339,046,304
EBITDA
$-249,476,992
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-1.59
Earnings per Share Estimate Next Year
Profit Margin
-201.18%
Shares Outstanding
300,040,992
Percent Owned by Insiders
9.07%
Percent Owned by Institutions
70.99%
52-Week High
52-Week Low

Technical Indicators for Pacific Biosciences of California

50-Day Moving Average
200-Day Moving Average
RSI
51.02
0.09

Analyst Ratings for Pacific Biosciences of California

Strong Buy
5
Buy
1
Hold
8
Sell
0
Strong Sell
0

News About Pacific Biosciences of California

May 8, 2025, 4:15 PM EST
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. See more.
May 7, 2025, 3:11 AM EST
Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be reporting results tomorrow after market close. See more.
May 5, 2025, 9:05 AM EST
MENLO PARK, Calif. and BANGKOK, May 05, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB) a leading provider of high-quality, highly accurate sequencing platforms, and Chulalongkorn University, a national leader in genomic and translational research, today announced a strategic collaboration to implement PacBio HiFi whole genome sequencing (WGS) as part of a newborn screening research program. See more.
May 5, 2025, 9:05 AM EST